Company News & Publications



Investigations of the mechanism behind the rapid absorption of nano-amorphous abiraterone acetate

Orsolya Basa-Dénes, Tamás Solymosi, Zsolt Ötvös, Réka Angi, Andrea Ujhelyi, Tamás Jordán, Gábor Heltovics, Hristos Galvinas
//Eur  J Pharm Sci. 2019 Mar 1;129:79-86 DOI: 10.1016/j.ejps.2019.01.001. Epub 2019 Jan 2.

» Read publication


Preparation, Pre-clinical and Clinical Evaluation of a Novel Rapidly Absorbed Celecoxib Formulation

Réka Angi, Tamás Solymosi, Nikolett Ersdosi, Tamás Jordán, Balázs Kárpáti, Orsolya Basa-Dénes, John McDermott,Chris Roe, Stuart Mair, Zsolt Ötvös, Hristos Glavinas // AAPS PharmSci Tech. 2019 Jan 25;20(2):90 DOI: 10.1208/s12249-018-1270-2

» Read publication



Solubility Measurements at 296 and 310 K and Physicochemical Characterization of Abiraterone and Abiraterone Acetate 

Tamás Solymosi, Ferenc Tóth, János Orosz, Orsolya Basa-Dénes, Réka Angi, Tamás Jordán, Zsolt Ötvös, Hristos Glavinas
// J. Chem. Eng. Data, 2018, 63 (12), pp 4453–4458 DOI: 10.1021/acs.jced.8b00566.

» Read publication


Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements

Tamás Solymosi, Zsolt Ötvös, Betti Ordasi, Tamás Jordán, Sándor Semsey, László Molnár, Soma Ránky, Genovéva Filipcsei, Gábor Heltovics, Hristos Glavinas //Int J Pharm. 2017 Sep 15;532(1):427-434.

» Read publication


Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect

Tamás Solymosi, Zsolt Ötvös, Réka Angi, Betti Ordasi, Tamás Jordán, László Molnár, John McDermott, Vanessa Zann, Ann Churc, Stuart Mair, Genovéva Filipcsei, Gábor Heltovics, Hristos Glavinas //Cancer Chemother Pharmacol. 2017 Aug 3.

» Read publication


Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method

Tamás Solymosi, Réka Angi, Orsolya Basa-Dénes, Soma Ránky , Zsolt Ötvös, Hristos Glavinas, Genovéva Filipcsei  and Gábor Heltovics //Eur J Pharm Biopharm. 2015 Aug;94:135-40.

» Read publication


Novel Continuous flow technology for the development of nanostructured Aprepitant formulation with improved pharmacocinetics properties

Réka Angi, Tamás Solymosi, Zsolt Ötvös, Betti Ordasi, Hristos Glavinas, Genovéva Filipcsei, Gábor Heltovics and Ferenc Darvas //Eur J Pharm Biopharm. 2014 Apr;86(3):361-8.

» Read publication


Flow chemistry for nanotechnology, Flow chemistry graduate textbook, Chapter 6, Vol.2.: Applications,  Ed. by Darvas, Ferenc / Hessel, Volker / Dorman, György, Walter de Gruyter, 2014, pp 161-187

Genovéva Filipcsei, Zsolt Ötvös, Réka Angi and Ferenc Darvas

» Read publication


News & Press releases

DRGT Announces First Subject Dosed in a Phase I Clinical Trial of DRGT 45, a Novel Formulation of Abiraterone Acetate for Prostate Cancer

BUDAPEST, Hungary, Oct. 29, 2019 -- Druggability Technologies Holdings (DRGT) today announces the first subject dosed in a two-part Phase I trial to evaluate the pharmacokinetics, safety, and oral bioavailability of DRGT-45 (abiraterone acetate tablets for oral suspension) to treat prostate cancer.

 » Read more


Druggability Technoliges Holdings, Ltd (DRGT) Announces Appointment of a New Chief Executive Officer and a New President of DRGT Research

BUDAPEST, Hungary, Oct. 21, 2019 -- Druggability Technologies Holdings, Ltd (DRGT), Ltd a clinical stage specialty pharmaceutical company, announced the appointment of Lynne Powell as Chief Executive Officer (CEO).  Lynne will also be joining the company’s Board of Directors.   Lynne will succeed Gabor Heltovics, who will continue to serve as President, DRGT Research and remain on the Board of Directors.

» Read more


DRGT Announces the U.S. FDA IND Application Approval and First Dosing of a Clinical Trial to Evaluate the Bioavailability and Food Effect of Immediate-Release Formulation of Tadalafil (DRGT-99)

BUDAPEST, Hungary, Sept. 18, 2019 -- Druggability Technologies Holdings today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a randomized, single-dose crossover study to evaluate the bioavailability and the impact of food on a novel immediate-release formulation of tadalafil (DRGT-99) compared with 20-mg tadalafil (Cialis®).

» Read more


DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients with chronic anal fissure

BUDAPEST, Hungary, July 15, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings today announced the start of a phase 2 randomized, double-blind, placebo-controlled trial to evaluate the optimal dose of DRGT-119 for the treatment of chronic anal fissure (CAF). DRGT-119 is an enhanced topical formulation of amlodipine, a calcium channel blocker (CCB).

» Read more



DRGT Completes a Pivotal Phase I Trial; Results Confirm 6x Faster Attainment of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor

BUDAPEST, Hungary, June 10, 2019 -- Druggability Technologies Holdings today announced results from a pharmacokinetic study of their novel formulation of celecoxib (“DRGT-46”), which achieves  faster time to maximum plasma concentration (Tmax) compared to traditional celecoxib capsules.

» Read more


DRGT USA Announces Appointment of Dr. Elizabeth Manning Duus, as Executive Director of Clinical Development

New York, Feb 5 2019. -- Druggability Technologies USA today announced the expansion of the clinical team, with the addition of Dr. Elizabeth Manning Duus, who has been named Executive Driector, Clinical Development.

» Read more



Druggability Technologies USA Announces Appointment of John E. Friend II, M.D. as Chief Medical Officer

New York, Dec 6. 2018 --Druggability Technologies USA today announced that Dr. John E. Friend II has been named as Chief Medical Officer. 
Druggability Technologies USA has been engaged by Druggability Technologies Holding (DRGT) to assist with the clinical develeopment of all human trials for DRGT.

» Read more


DRGT wins Best Oral Presentation Award at EUFEPS Annual Meeting 2018

We are proud to announce that DRGT's scientific presentation


presented by Hristos Glavinas, CSO of DRGT, was selected as Best Oral Presentation at the EUFEPS Annual Meeting 2018.

» See the Award



Best in Class Erectile Dysfunction Drug - DRGT announces dose escalation study results of its Super-Tadalafil DRGT-99

MALTA, May 02, 2018 - DRGT, a specialty pharmaceutical company with a proprietary formulation technology, announced the results of its successful dose escalation PK study for DRGT-99, an innovative formulation of tadalafil. 

» Read more


DRGT announces results of Phase I study expanding clinical utility of the drug Sirolimus utilizing the company's novel Super-API technology platform

MSIDA, Malta, Oct. 05, 2017 - DRGT, a specialty pharmaceutical company, today announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®), originally a Pfizer product approved by the FDA.

» Read more


DRGT’s novel Celecoxib composition – opportunity for low dose, immediate onset of pain relief with the only NSAID COX-2 inhibitor on the market

19th December 2016, Swatar, Malta - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-46 and DRGT-47 programs, new compositions of Celecoxib – a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). 

» Read more


Dr. Philip Kantoff - leading expert in clinical oncology and prostate cancer joins DRGT as Senior Clinical Advisor

14th December 2016, Malta - DRGT, a specialty pharmaceutical company announced today that Dr. Philip Kantoff joined the leadership as Senior Clinical Advisor to accelerate the progress of its ambitious oncology drug development program.

» Read more


DRGT’s novel Abiraterone Acetate composition – an opportunity for dose reduction and increased efficacy in prostate cancer

9th December 2016, Malta - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-45 program, a new composition of Abiraterone Acetate - a major drug in the fight against metastatic, castration-resistant prostate cancer.

» Read more


Quotient Clinical begins prostate cancer project for Druggability Technologies

June 23, 2015 - Quotient Clinical, the Translational Pharmaceutics® Company, initiates a new RapidFACT program for Druggability Technologies (DRGT) for evaluating enhanced formulations of abiratone acetate.

» Read more

Druggability Technologies enters into a strategic collaboration with Bayer HealthCare

DRGT signs a broad collaboration agreement with Bayer HealthCare to leverage DRGT’s Super-API Technology to accelerate the discovery and development of novel drugs.

» Read more